Elevation Oncology Past Earnings Performance
Past criteria checks 0/6
Elevation Oncology's earnings have been declining at an average annual rate of -31.9%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-31.9%
Earnings growth rate
64.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -51.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
May 03Elevation Oncology: Rising On News, But Not The Time To Buy
Jan 17Elevation Oncology GAAP EPS of -$0.86 misses by $0.07
Aug 04Elevation Oncology secured $50M loan facility with K2 HealthVentures
Jul 28We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely
May 10
We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate
Jan 25Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth
Sep 25Revenue & Expenses BreakdownBeta
How Elevation Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -39 | 14 | 24 |
| 31 Dec 23 | 0 | -46 | 15 | 25 |
| 30 Sep 23 | 0 | -57 | 16 | 35 |
| 30 Jun 23 | 0 | -85 | 16 | 62 |
| 31 Mar 23 | 0 | -95 | 16 | 72 |
| 31 Dec 22 | 0 | -95 | 16 | 79 |
| 30 Sep 22 | 0 | -86 | 15 | 70 |
| 30 Jun 22 | 0 | -59 | 14 | 45 |
| 31 Mar 22 | 0 | -44 | 11 | 33 |
| 31 Dec 21 | 0 | -32 | 8 | 24 |
| 30 Sep 21 | 0 | -31 | 6 | 26 |
| 30 Jun 21 | 0 | -22 | 3 | 19 |
| 31 Mar 21 | 0 | -20 | 2 | 18 |
| 31 Dec 20 | 0 | -17 | 2 | 15 |
Quality Earnings: ELEV is currently unprofitable.
Growing Profit Margin: ELEV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ELEV is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare ELEV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ELEV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ELEV has a negative Return on Equity (-51.9%), as it is currently unprofitable.